Abatacept in Immune Checkpoint Inhibitor Myocarditis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 390 participants.

Also called NCT05335928

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 390 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05335928
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05335928. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-02 (actual); primary completion 2029-04-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Acronym
ATRIUM
Condition
Myocarditis Acute
Condition
Cancer
Intervention (Drug)
Abatacept plus
Intervention (Drug)
Placebo
Lead sponsor
Massachusetts General Hospital (class: other)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct05335928
Content hash
cc436244c2de6986d13e7f103f40069c6d2b2f48989a5d089d520ad964304111